A GLOBAL, PHASE 1/2, OPEN-LABEL, DOSE OPTIMIZATION STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACODYNAMICS, AND PHARMACOKINETICS OF MRNA-3705 IN PARTICIPANTS WITH ISOLATED METHYLMALONIC ACIDEMIA DUE TO METHYLMALONYL-COA MUTASE DEFICIENCY

Registry ID

MRNA-3705-P101

Source registry

HEALTH_CANADA

Status

Ongoing

Phase

PHASE1

Study type

INTERVENTIONAL

Sponsor

MODERNATX, INC.

Start date

2022-08-10

Last update

2021-04-08

Conditions

• METHYLMALONIC ACIDEMIA

View on source registry